ImmunityBio Earnings
NASDAQ: IBRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Tue, Nov 3, 2026
Fiscal period
Sep/2026
EPS estimate
$-0.08
ImmunityBio earnings summary
ImmunityBio is scheduled to report Sep/2026 earnings on Nov 3, 2026, with analysts expecting EPS of $-0.08. In its most recent report on Aug 4, 2026 (Q2 2026), IBRX posted EPS of $-0.22. Revenue for the quarter was $51.2 million.
Across the last 16 reports, IBRX shares moved an average of 11.2% (in either direction) in the first trading session after results, rising 5 times and falling 11 times.
Summary generated from market data by MetaCap's automated system. Methodology
IBRX earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 4, 2026 | — | $-0.22 | — | -0.9% |
| May 7, 2026 | — | $-0.62 | — | -6.3% |
| Feb 23, 2026 | — | $-0.06 | — | -11.3% |
| Nov 5, 2025 | — | $-0.07 | — | -2.3% |
| Aug 5, 2025 | — | $-0.10 | — | +4.5% |
| May 12, 2025 | — | $-0.15 | — | -10.9% |
| Mar 3, 2025 | — | $-0.08 | — | -4.3% |
| Nov 12, 2024 | — | $-0.14 | — | +13.6% |
| Aug 12, 2024 | — | $-0.20 | — | +6.0% |
| May 9, 2024 | — | $-0.20 | — | -5.8% |
| Mar 19, 2024 | — | $-0.37 | — | -11.5% |
| Nov 9, 2023 | — | $-0.19 | — | +33.1% |
| Aug 8, 2023 | — | $-0.32 | — | -1.1% |
| May 11, 2023 | — | $-0.27 | — | +30.3% |
| Mar 1, 2023 | — | $-0.26 | — | -27.3% |
| Nov 9, 2022 | — | $-0.28 | — | -9.8% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.